Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy [3] - The company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line [3] - Jupiter's proprietary formulation, JOTROL, has shown improved bioavailability in clinical studies and is central to both its prescription pipeline and consumer products [3] Product Offerings - The prescription pipeline includes a Phase IIa clinical trial for Parkinson's disease and targets other CNS disorders such as Alzheimer's Disease and Friedreich's Ataxia [3] - Nugevia, the consumer longevity product line, features three formulations: PWR (mitochondrial support), MND (cognitive health), and GLO (skin vitality), utilizing the same JOTROL technology [4] - Products are available direct-to-consumer and the company is expanding into practitioner-led channels to leverage the clinical-grade bioavailability of its formulations [4] Conference Participation - Jupiter has been invited to present its clinical and commercial progress at the Emerging Growth Conference on April 2, 2026, at 10:15 AM ET, inviting both individual and institutional investors to attend [1] - An archived webcast of the presentation will be available post-event for those unable to attend live [1][2]

Core Insights - Jupiter Neurosciences, Inc. is advancing its FDA-cleared Phase IIa clinical program targeting Parkinson's disease, with a focus on neuroinflammation and central nervous system disorders [2][5] - The company is also generating revenue through its consumer product Nugevia, which utilizes the patented JOTROL technology to enhance resveratrol bioavailability [3][5] Clinical Development - The FDA granted the Investigational New Drug (IND) application for the Phase IIa trial in November 2025, following preclinical data showing a nine-fold improvement in JOTROL bioavailability compared to standard resveratrol formulations [2] - The clinical program is supported by translational proof-of-concept data from Parkinson's disease models, which underpins the scientific rationale for the trial [2] Revenue Generation - Nugevia has demonstrated early commercial validation with a repeat purchase rate of approximately 25% and a product return rate of about 3%, indicating a capital-efficient operating model [3] - The dual-path strategy of combining clinical development with revenue generation through Nugevia differentiates Jupiter from other biotechnology peers that rely solely on external financing [3][5] Management's Outlook - The CEO expressed confidence in the company's execution plan and the importance of achieving clinical milestones while continuing to build revenue through Nugevia [4] - Management will engage with investors and potential partners at the BIO Investment and Growth Summit 2026, highlighting the company's commitment to disciplined execution [3][4]

Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing JOTROL™, a patented resveratrol-based platform aimed at addressing neuroinflammation and promoting healthy aging [3] - The company is pursuing a dual-path strategy that includes a therapeutic pipeline for central nervous system (CNS) disorders and rare diseases, as well as a consumer longevity market through its Nugevia product line [3] - JOTROL™ has shown significantly improved bioavailability, enhancing its therapeutic potential [3] Upcoming Event - Jupiter Neurosciences will participate in the DealFlow Discovery Conference on January 28-29, 2026, where the Chairman and CEO, Christer Rosén, will present the company and hold one-on-one investor meetings [1][2] - Investors can attend the conference at no cost and are encouraged to schedule meetings with the management team [2] Product Pipeline - The company's prescription pipeline is currently focused on CNS disorders, with a Phase IIa clinical trial ongoing for Parkinson's disease, and includes indications for Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS [3] - Nugevia, the consumer product line, aims to bring clinical-grade science to the supplement market, supporting mental clarity, skin health, and mitochondrial function [3]

Core Insights - Jupiter Neurosciences is advancing its JOTROL platform into a Phase 2a clinical trial for Parkinson's disease, marking a significant regulatory milestone with FDA clearance [4][5] - The company launched its Nugevia consumer brand, targeting the $8 trillion longevity market, with initial products designed to enhance brand visibility and generate revenue [6][7] - Jupiter has secured strategic financing of up to $20 million to support its clinical and commercial initiatives, providing flexibility and control over capital access [10][11][12] Company Achievements - Jupiter Neurosciences completed its first full year as a public company, establishing a foundation for long-term value creation and executing major initiatives [2][3] - The JOTROL platform has demonstrated a nine-fold improvement in bioavailability and effective blood-brain barrier penetration, supporting its therapeutic potential [5][20] - The Nugevia product line includes three initial offerings—GLO, PWR, and MND—integrating JOTROL with other bioavailable ingredients to support various aspects of health [7][21] Market Positioning - The Nugevia brand is supported by high-profile ambassadors, enhancing its market presence and performance-driven identity [8] - A dedicated website for Nugevia was launched, facilitating pre-orders and establishing a subscription-based model for recurring revenue [9] - Jupiter's dual-path strategy focuses on both therapeutic applications for CNS disorders and consumer longevity products, positioning the company for growth in both sectors [17][22] Financial Strategy - The strategic financing agreement with Yorkville Advisors allows Jupiter to access capital as needed, ensuring stability during its growth phase [10][11] - The financing structure is designed to be non-toxic and fully controlled by the company, allowing for advantageous capital access [11][12] - The company aims to strengthen its financial position while supporting ongoing operations and clinical trials without compromising shareholder interests [12]

Core Insights - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing JOTROL™, a resveratrol-based therapeutic platform aimed at neuroinflammation and mitochondrial dysfunction [1][4] - The company will present at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, providing opportunities for one-on-one meetings with investors [1][2] Company Overview - Jupiter Neurosciences is pursuing a dual-path strategy to address neuroinflammation and promote healthy aging, targeting CNS disorders and rare diseases while also entering the consumer longevity market with its Nugevia product line [4] - The therapeutic pipeline includes a Phase IIa trial for Parkinson's disease and indications such as Alzheimer's Disease and Friedreich's Ataxia [4] Product Details - JOTROL™ has demonstrated over nine times higher bioavailability compared to earlier resveratrol products, addressing the issue of poor bioavailability that has hindered regulatory approval for resveratrol [6] - The Nugevia product line leverages the same clinically validated delivery technology as JOTROL™, offering support for cognitive health, skin vitality, and cellular energy [7]

As filed with the Securities and Exchange Commission on November 26, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-4828381 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Jupiter Neu ...

Core Insights - Jupiter Neurosciences, Inc. has received FDA clearance for its Investigational New Drug application to initiate a Phase 2a clinical trial of JOTROL for Parkinson's disease [1][2][3] - The Phase 2a trial aims to evaluate the safety and tolerability of JOTROL, with additional endpoints to assess pharmacokinetics and pharmacodynamics [2][3] - JOTROL has shown strong safety and bioavailability in Phase I studies, with preclinical evidence suggesting potential neuroprotective benefits [3][4] Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on neuroinflammation and healthy aging, with a therapeutic pipeline targeting CNS disorders and rare diseases [6] - The company is advancing JOTROL, a proprietary resveratrol formulation, which has demonstrated over nine-fold higher bioavailability compared to traditional resveratrol [4][8] - Jupiter is also expanding into the consumer longevity market with its Nugevia product line, which leverages the same delivery technology as JOTROL [6][9] Market Context - Parkinson's disease affects over 10 million people globally, with no current disease-modifying treatments available, highlighting a significant unmet medical need [5] - The global market for Parkinson's therapeutics is projected to exceed $14 billion by 2030, indicating a strong demand for innovative treatments [5]

Core Insights - Jupiter Neurosciences, Inc. has entered into two strategic financing agreements with Yorkville Advisors Global, LP, allowing access to up to $20 million in capital to support its Phase 2 trial for Parkinson's disease and to accelerate the growth of its Nugevia product line [1][2][6] Financing Details - The financing includes a $4 million pre-paid advance available upon execution of the agreements, with an additional $2 million expected shortly after the effectiveness of a registration statement [3] - The pre-paid advances will be issued at a 7% original issue discount and will bear interest, with a maturity date of 12 months after signing [3] - The company has the option to sell up to $14 million of common stock over a 24-month period under a standby equity purchase agreement (SEPA), with shares issued at a 3.0% discount to market price [4][7] Product and Market Focus - The proceeds from the financing will primarily support the Phase 2 trial of JOTROL, a resveratrol delivery platform for treating Parkinson's disease, and will also be used for marketing and sales growth of the Nugevia nutritional product line [2][6] - Jupiter Neurosciences is advancing a therapeutic pipeline targeting CNS disorders and rare diseases, while also expanding into the consumer longevity market with Nugevia [6][10] JOTROL and Nugevia - JOTROL has demonstrated over nine times higher bioavailability compared to earlier resveratrol products, addressing the issue of poor bioavailability that has hindered regulatory approval [9] - Nugevia leverages the same clinically validated delivery technology as JOTROL, offering targeted support for cognitive health, skin vitality, and cellular energy [10]

Core Insights - Jupiter Neurosciences, Inc. has appointed Jean Fallacara as the brand ambassador for its new consumer longevity supplement line, Nugevia, which aims to enhance clinical and scientific integrity in the longevity market [2][4][5] - Nugevia is built on the JOTROL platform, a patented resveratrol-based micellar delivery system that significantly improves bioavailability, supporting the company's clinical-stage CNS therapies [5][11] - The longevity market is projected to reach $8 trillion by 2030, and Nugevia's consumer-facing strategy is expected to create a revenue stream that supports ongoing clinical development and enhances long-term shareholder value [6][8] Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy, which includes advancing therapeutics for CNS disorders and expanding into the consumer longevity market with Nugevia [8] - The company’s therapeutic pipeline includes a Phase IIa trial for Parkinson's disease and targets other CNS disorders such as Alzheimer's Disease and Friedreich's Ataxia [8][10] - JOTROL, the foundation for both therapeutic and consumer products, has demonstrated over nine times higher bioavailability compared to earlier resveratrol products, addressing the issue of poor absorption that has historically limited the effectiveness of resveratrol [9][10][11] Product Details - Nugevia's initial formulations—GLO, MND, and PWR—are designed to support cellular resilience through synergistic ingredients optimized for absorption via the JOTROL system [5][11] - The brand emphasizes the importance of real science in wellness innovation, aiming to make human longevity accessible to a broad audience, including athletes and entrepreneurs [5][6]

Core Insights - Jupiter Neurosciences, Inc. is advancing its proprietary resveratrol-based platform, JOTROL, which offers significant advantages over traditional resveratrol formulations [1][3][10] - JOTROL has demonstrated a nine-fold increase in bioavailability compared to conventional resveratrol, while avoiding gastrointestinal side effects [3][7][10] - The company is progressing JOTROL towards a Phase IIa trial for Parkinson's Disease, supported by promising preclinical data [4][8][10] Scientific and Clinical Advantages - Resveratrol is known for its antioxidant, mitochondrial, and anti-inflammatory properties, but its therapeutic use has been limited due to poor bioavailability and GI side effects [2][9] - JOTROL promotes mitochondrial biogenesis and reduces neuroinflammation, addressing key factors in neurodegenerative diseases and aging [5][6] Product Development and Market Strategy - JOTROL is not only aimed at pharmaceutical applications but also serves as the foundation for the Nugevia consumer product line, targeting cognitive health, mitochondrial energy, and skin vitality [4][11] - The Nugevia product line is set to launch in Q3 2025, leveraging the same delivery technology as JOTROL to provide clinical-grade bioavailability in the wellness market [11] Intellectual Property and Market Potential - The company has secured intellectual property rights for JOTROL in major markets including the U.S., EU, China, Japan, and Hong Kong, valid through 2036 [7] - JOTROL's ability to cross the blood-brain barrier positions it as a potential treatment for CNS disorders such as Parkinson's and Alzheimer's [7][8]